

Tara Gomes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3098299/publications.pdf>

Version: 2024-02-01

281
papers

10,533
citations

47006

47
h-index

40979

93
g-index

287
all docs

287
docs citations

287
times ranked

12211
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Analgesic Use After Low-Risk Surgery. <i>Archives of Internal Medicine</i> , 2012, 172, 425.	3.8	669
2	A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. <i>Cmaj</i> , 2009, 180, 713-718.	2.0	622
3	Opioid Dose and Drug-Related Mortality in Patients With Nonmalignant Pain. <i>Archives of Internal Medicine</i> , 2011, 171, 686-91.	3.8	531
4	The Burden of Opioid-Related Mortality in the United States. <i>JAMA Network Open</i> , 2018, 1, e180217.	5.9	484
5	Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. <i>PLoS Medicine</i> , 2017, 14, e1002396.	8.4	362
6	Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. <i>BMJ: British Medical Journal</i> , 2010, 340, c693-c693.	2.3	358
7	Risk of incident diabetes among patients treated with statins: population based study. <i>BMJ, The</i> , 2013, 346, f2610-f2610.	6.0	338
8	Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2634.	7.4	303
9	Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia. <i>Archives of Internal Medicine</i> , 2008, 168, 1090.	3.8	208
10	Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. <i>Headache</i> , 2015, 55, 221-235.	3.9	197
11	The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly. <i>Archives of Internal Medicine</i> , 2012, 172, 1739.	3.8	159
12	Rates of hemorrhage during warfarin therapy for atrial fibrillation. <i>Cmaj</i> , 2013, 185, E121-E127.	2.0	159
13	Variation in Nursing Home Antipsychotic Prescribing Rates. <i>Archives of Internal Medicine</i> , 2007, 167, 676.	3.8	155
14	Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. <i>CMAJ Open</i> , 2015, 3, E166-E171.	2.4	154
15	Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. <i>BMJ: British Medical Journal</i> , 2009, 339, b2942-b2942.	2.3	150
16	Statin Toxicity From Macrolide Antibiotic Coprescription. <i>Annals of Internal Medicine</i> , 2013, 158, 869.	3.9	132
17	Opioid Dose and Risk of Road Trauma in Canada. <i>JAMA Internal Medicine</i> , 2013, 173, 196.	5.1	127
18	The burden of premature opioid-related mortality. <i>Addiction</i> , 2014, 109, 1482-1488.	3.3	125

#	ARTICLE	IF	CITATIONS
19	Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0134550.	2.5	124
20	Pregabalin and the Risk for Opioid-Related Death: A Nested Caseâ€“Control Study. Annals of Internal Medicine, 2018, 169, 732.	3.9	116
21	Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ, The, 2015, 350, h2298-h2298.	6.0	115
22	Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. JAMA - Journal of the American Medical Association, 2017, 317, 1544.	7.4	114
23	Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ: British Medical Journal, 2018, 362, k3207.	2.3	103
24	Trimethoprim-Sulfamethoxazoleâ€“Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System. Archives of Internal Medicine, 2010, 170, 1045.	3.8	102
25	Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults. Annals of Internal Medicine, 2013, 158, 447.	3.9	88
26	Trends in high-dose opioid prescribing in Canada. Canadian Family Physician, 2014, 60, 826-32.	0.4	85
27	Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ, The, 2014, 349, g6196-g6196.	6.0	84
28	Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiatry, the, 2018, 5, 644-652.	7.4	83
29	Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Medicine, 2018, 15, e1002584.	8.4	82
30	Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Canadian Family Physician, 2011, 57, e92-6.	0.4	79
31	The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. Cmaj, 2011, 183, 303-307.	2.0	69
32	Persistence With Therapy Among Patients Treated With Warfarin for Atrial Fibrillation. Archives of Internal Medicine, 2012, 172, 1687.	3.8	69
33	Relationship of asthma management, socioeconomic status, and medication insurance characteristics to exacerbation frequency in children with asthma. Annals of Allergy, Asthma and Immunology, 2011, 106, 17-23.	1.0	68
34	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. Chest, 2017, 152, 81-91.	0.8	68
35	Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Medicine, 2011, 5, e13-22.	1.5	67
36	â€œLike being put on an ice floe and shoved awayâ€“: A qualitative study of the impacts of opioid-related policy changes on people who take opioids. International Journal of Drug Policy, 2019, 66, 15-22.	3.3	63

#	ARTICLE	IF	CITATIONS
37	Geographical Variation in Opioid Prescribing and Opioid-Related Mortality in Ontario. <i>Healthcare Quarterly</i> , 2011, 14, 22-24.	0.7	62
38	Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis. <i>CMAJ Open</i> , 2014, 2, E256-E261.	2.4	62
39	Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ: British Medical Journal</i> , 2011, 343, d5228-d5228.	2.3	61
40	Orlistat and Acute Kidney Injury: An Analysis of 953 Patients. <i>Archives of Internal Medicine</i> , 2011, 171, 702.	3.8	60
41	Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study. <i>PLoS Medicine</i> , 2014, 11, e1001736.	8.4	60
42	Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study. <i>Pain</i> , 2018, 159, 1562-1568.	4.2	60
43	Preventing Pressure Ulcers in Long-term Care. <i>Archives of Internal Medicine</i> , 2011, 171, 1839.	3.8	56
44	Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 361-369.	1.9	56
45	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <i>Cmaj</i> , 2015, 187, 174-180.	2.0	54
46	Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2112865.	5.9	54
47	Predictors of Opioid-Related Death During Methadone Therapy. <i>Journal of Substance Abuse Treatment</i> , 2015, 57, 30-35.	2.8	52
48	Inviting Patients to Read Doctors' Notes. <i>Annals of Internal Medicine</i> , 2012, 156, 608.	3.9	50
49	Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>Cmaj</i> , 2015, 187, E138-E143.	2.0	50
50	Oral bisphosphonate use in the elderly is not associated with acute kidney injury. <i>Kidney International</i> , 2012, 82, 903-908.	5.2	46
51	Statins and the Risk of Herpes Zoster: A Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 350-356.	5.8	45
52	Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 419-429.	2.8	45
53	Toxic Megacolon in Children With Inflammatory Bowel Disease: Clinical and Radiographic Characteristics. <i>American Journal of Gastroenterology</i> , 2008, 103, 1524-1531.	0.4	44
54	High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study. <i>PLoS ONE</i> , 2016, 11, e0167479.	2.5	43

#	ARTICLE	IF	CITATIONS
55	Measuring the Burden of Opioid-related Mortality in Ontario, Canada. <i>Journal of Addiction Medicine</i> , 2018, 12, 418-419.	2.6	43
56	Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 846.	7.4	43
57	Risk of Acute Kidney Injury From Oral Acyclovir: A Population-Based Study. <i>American Journal of Kidney Diseases</i> , 2013, 61, 723-729.	1.9	42
58	Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada. <i>Journal of Addiction Medicine</i> , 2015, 9, 440-446.	2.6	42
59	Macrolide-Induced Digoxin Toxicity: A Population-Based Study. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 383-386.	4.7	41
60	Neonatal opioid withdrawal and antenatal opioid prescribing. <i>CMAJ Open</i> , 2015, 3, E55-E61.	2.4	41
61	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. <i>Cmaj</i> , 2017, 189, E4-E10.	2.0	41
62	Effect on Treatment Adherence of Distributing Essential Medicines at No Charge. <i>JAMA Internal Medicine</i> , 2020, 180, 27.	5.1	41
63	Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario. <i>Quality of Life Research</i> , 2010, 19, 81-89.	3.1	37
64	Risk of Serious Falls Associated With Oxybutynin and Tolterodine: A Population Based Study. <i>Journal of Urology</i> , 2011, 186, 1340-1344.	0.4	36
65	Risk of serious medical events in patients with depression treated with electroconvulsive therapy: a propensity score-matched, retrospective cohort study. <i>Lancet Psychiatry</i> , 2021, 8, 686-695.	7.4	36
66	New Opioid Use after Invasive Mechanical Ventilation and Hospital Discharge. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 568-575.	5.6	34
67	Blood glucose test strips: options to reduce usage. <i>Cmaj</i> , 2010, 182, 35-38.	2.0	33
68	Association between perioperative beta blocker use and cancer survival following surgical resection. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1164-1169.	1.0	31
69	Ciprofloxacin-induced theophylline toxicity: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 521-526.	1.9	30
70	Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: A retrospective cohort study. <i>Clinical Toxicology</i> , 2012, 50, 390-395.	1.9	30
71	Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1888-1894.	0.7	29
72	The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation. <i>PLoS ONE</i> , 2016, 11, e0149142.	2.5	29

#	ARTICLE	IF	CITATIONS
73	Antiepileptic use for epilepsy and nonepilepsy disorders. <i>Neurology</i> , 2016, 86, 939-946.	1.1	29
74	Comparative adherence to oxybutynin or tolterodine among older patients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 97-99.	1.9	28
75	The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men. <i>PLoS ONE</i> , 2014, 9, e98003.	2.5	28
76	Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study. <i>American Heart Journal</i> , 2015, 170, 133-140.e3.	2.7	28
77	Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other CNS-Active Medications: A Cross-Sectional Time Series Analysis. <i>Pain Medicine</i> , 2017, 18, 1019-1026.	1.9	28
78	The Safety of Proton Pump Inhibitors and Clopidogrel in Patients After Stroke. <i>Stroke</i> , 2011, 42, 128-132.	2.0	27
79	The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study. <i>PLoS ONE</i> , 2019, 14, e0223589.	2.5	27
80	Opioid prescribing is a surrogate for inadequate pain management resources. <i>Canadian Family Physician</i> , 2016, 62, 465-8.	0.4	27
81	Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 544-549.	2.4	26
82	Beta-Blockers, Trimethoprim-Sulfamethoxazole, and the Risk of Hyperkalemia Requiring Hospitalization in the Elderly. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1544-1551.	4.5	25
83	Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. <i>CMAJ Open</i> , 2017, 5, E800-E807.	2.4	25
84	Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study. <i>Drug and Alcohol Dependence</i> , 2018, 191, 86-90.	3.2	24
85	Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1591-1598.	0.7	23
86	Use of other opioids during methadone therapy: a population-based study. <i>Addiction</i> , 2012, 107, 776-780.	3.3	23
87	Hospitalization for Hemorrhage Among Warfarin Recipients Prescribed Amiodarone. <i>American Journal of Cardiology</i> , 2013, 112, 420-423.	1.6	23
88	Opioid Use and Overdose: What We've Learned in Ontario. <i>Healthcare Quarterly</i> , 2016, 18, 8-11.	0.7	23
89	Adverse Cardiac Events in Older Patients Receiving Venlafaxine. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e552-e558.	2.2	23
90	Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. <i>Diabetic Medicine</i> , 2012, 29, 1524-1528.	2.3	22

#	ARTICLE	IF	CITATIONS
91	Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. <i>International Journal of Drug Policy</i> , 2022, 102, 103601.	3.3	22
92	Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study. <i>Canadian Journal of Cardiology</i> , 2016, 32, 986.e17-986.e22.	1.7	21
93	Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study. <i>Cmaj</i> , 2018, 190, E1376-E1383.	2.0	21
94	Metronidazole-associated Neurologic Events: A Nested Case-control Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 2095-2100.	5.8	21
95	Temporal Trend of Carpal Tunnel Release Surgery: A Population-Based Time Series Analysis. <i>PLoS ONE</i> , 2014, 9, e97499.	2.5	21
96	Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions. <i>BMJ Open</i> , 2013, 3, e002857.	1.9	20
97	Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2483-2488.	2.8	20
98	Prescription Stimulant Use and Hospitalization for Psychosis or Mania. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 667-671.	1.4	20
99	Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 758-765.	1.9	20
100	Availability of naloxone in Canadian pharmacies:a population-based survey. <i>CMAJ Open</i> , 2017, 5, E779-E784.	2.4	20
101	Association of Opioid Consumption Profiles After Hospitalization With Risk of Adverse Health Care Events. <i>JAMA Network Open</i> , 2021, 4, e218782.	5.9	20
102	Sensitivity and specificity of administrative mortality data for identifying prescription opioid-related deaths. <i>Cmaj</i> , 2016, 188, E67-E72.	2.0	19
103	Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. <i>JAMA Network Open</i> , 2019, 2, e1913304.	5.9	19
104	One-Year Mortality After Emergency Department Visit for Nonfatal Opioid Poisoning: A Population-Based Analysis. <i>Annals of Emergency Medicine</i> , 2020, 75, 20-28.	0.6	19
105	Opioid Prescribing Practices for Women Undergoing Elective Gynecologic Surgery. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1325-1333.e3.	0.6	19
106	Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. <i>Cmaj</i> , 2013, 185, 1035-1041.	2.0	18
107	Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. <i>Implementation Science</i> , 2015, 11, 45.	6.9	18
108	Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. <i>Drug and Alcohol Dependence</i> , 2017, 177, 315-321.	3.2	18

#	ARTICLE	IF	CITATIONS
109	Prevalence and characteristics of opioid-related deaths involving alcohol in Ontario, Canada. <i>Drug and Alcohol Dependence</i> , 2017, 179, 416-423.	3.2	18
110	Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 59-65.e2.	1.0	18
111	Quality of primary care among individuals receiving treatment for opioid use disorder. <i>Canadian Family Physician</i> , 2019, 65, 343-351.	0.4	18
112	A Population-Based Assessment of the Drug Interaction Between Levothyroxine and Warfarin. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 766-770.	4.7	17
113	Altered mental status in older adults with histamine2-receptor antagonists: A population-based study. <i>European Journal of Internal Medicine</i> , 2014, 25, 701-709.	2.2	17
114	Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. <i>JAMA Network Open</i> , 2021, 4, e2130795.	5.9	17
115	Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis. <i>International Journal of Drug Policy</i> , 2022, 103, 103644.	3.3	17
116	Selective Serotonin Reuptake Inhibitors and Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 348-353.	0.8	16
117	Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits. <i>BMJ Open</i> , 2019, 9, e026705.	1.9	16
118	Understanding the Implications of a Shifting Opioid Landscape in Ontario. <i>Healthcare Quarterly (Toronto, Ont)</i> , 2019, 22, 6-11.	0.5	16
119	Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 739-745.	4.7	16
120	A qualitative study of a publicly funded pharmacy-dispensed naloxone program. <i>International Journal of Drug Policy</i> , 2021, 92, 103146.	3.3	16
121	Trends in Hospitalizations for Serious Infections Among People With Opioid Use Disorder in Ontario, Canada. <i>Journal of Addiction Medicine</i> , 2022, 16, 433-439.	2.6	16
122	Risk of suicide death following electroconvulsive therapy treatment for depression: a propensity score-weighted, retrospective cohort study in Canada. <i>Lancet Psychiatry</i> , 2022, 9, 435-446.	7.4	16
123	Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers and Cardiovascular Outcomes in Chronic Dialysis Patients: A Population-Based Cohort Study. <i>Archives of Internal Medicine</i> , 2012, 172, 591-3.	3.8	15
124	Trends in selection and timing of first-line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006. <i>Diabetic Medicine</i> , 2013, 30, 1209-1213.	2.3	15
125	The Ontario Drug Policy Research Network: Bridging the gap between Research and Drug Policy. <i>Health Policy</i> , 2014, 117, 392-398.	3.0	15
126	Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes. <i>JAMA Internal Medicine</i> , 2017, 177, 61.	5.1	15

#	ARTICLE	IF	CITATIONS
127	Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage. <i>JAMA Network Open</i> , 2019, 2, e1917053.	5.9	15
128	Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study. <i>BMJ</i> , The, 2021, 375, e066965.	6.0	15
129	No Increase in Adverse Events During Aliskiren Use Among Ontario Patients Receiving Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers. <i>Canadian Journal of Cardiology</i> , 2013, 29, 586-591.	1.7	14
130	Regional variation in healthcare spending and mortality among senior high-cost healthcare users in Ontario, Canada: a retrospective matched cohort study. <i>BMC Geriatrics</i> , 2018, 18, 262.	2.7	14
131	Opioid prescribing and adverse events in opioid-naïve patients treated by emergency physicians versus family physicians: a population-based cohort study. <i>CMAJ Open</i> , 2018, 6, E110-E117.	2.4	14
132	Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study. <i>CMAJ Open</i> , 2019, 7, E582-E589.	2.4	14
133	Impact of delisting high-strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 726-733.	1.9	14
134	Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. <i>Value in Health</i> , 2020, 23, 1137-1141.	0.3	14
135	Evaluation of opioid discontinuation after non-orthopaedic surgery among chronic opioid users: a population-based cohort study. <i>British Journal of Anaesthesia</i> , 2020, 124, 281-291.	3.4	14
136	Prevalence of Prenatal Opioid Exposure in Ontario, Canada, 2014-2019. <i>JAMA Network Open</i> , 2021, 4, e2037388.	5.9	14
137	The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. <i>Depression and Anxiety</i> , 2022, 39, 156-162.	4.1	14
138	Comparative adherence to oxybutynin or tolterodine among older patients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1121-1121.	1.9	13
139	Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study. <i>BMC Nephrology</i> , 2014, 15, 79.	1.8	13
140	Pregabalin and heart failure: a population-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1087-1092.	1.9	13
141	Opioid Use After ICU Admission Among Elderly Chronic Opioid Users in Ontario: A Population-Based Cohort Study. <i>Critical Care Medicine</i> , 2018, 46, 1934-1942.	0.9	13
142	Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults. <i>Canadian Geriatrics Journal</i> , 2018, 21, 269-273.	1.2	13
143	Patient-level Characteristics and Inequitable Access to Inpatient Electroconvulsive Therapy for Depression: A Population-based Cross-sectional Study: Caractéristiques au niveau du patient et accès inéquitable à la thérapie électroconvulsive pour patients hospitalisés. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 147-158.	1.9	13
144	Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. <i>Cmaj</i> , 2021, 193, E304-E309.	2.0	13

#	ARTICLE	IF	CITATIONS
145	Hospital Admissions for Hyperkalemia With Trimethoprim-Sulfamethoxazole: A Cohort Study Using Health Care Database Codes for 393,039 Older Women With Urinary Tract Infections. <i>American Journal of Kidney Diseases</i> , 2011, 57, 521-523.	1.9	12
146	Antidepressants, metoprolol and the risk of bradycardia. <i>Therapeutic Advances in Psychopharmacology</i> , 2012, 2, 43-49.	2.7	12
147	Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. <i>Drugs - Real World Outcomes</i> , 2016, 3, 175-182.	1.6	12
148	Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes. <i>JAMA Network Open</i> , 2020, 3, e205724.	5.9	12
149	Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 950-960.	4.4	12
150	Initial opioid prescription patterns and the risk of ongoing use and adverse outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 379-389.	1.9	12
151	Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2320-2328.	4.4	12
152	A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 662-669.	2.4	11
153	Self-Monitoring of Blood Glucose Levels: Evaluating the Impact of a Policy of Quantity Limits on Test-Strip Use and Costs. <i>Canadian Journal of Diabetes</i> , 2016, 40, 431-435.	0.8	11
154	Factors that may be influencing the rise in prescription testosterone replacement therapy in adult men: a qualitative study. <i>Aging Male</i> , 2016, 19, 90-95.	1.9	11
155	Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. <i>Canadian Journal of Diabetes</i> , 2019, 43, 179-185.e1.	0.8	11
156	Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018). <i>Canadian Journal of Public Health</i> , 2021, 112, 89-96.	2.3	11
157	Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis. <i>Addiction</i> , 2021, 116, 1514-1520.	3.3	11
158	Effects of Funding Policy Changes and Health Warnings on the Use of Erythropoiesis-Stimulating Agents. <i>Journal of Oncology Practice</i> , 2012, 8, 179-183.	2.5	10
159	Upper Gastrointestinal Bleeding in Elderly Adults with Dementia Receiving Cholinesterase Inhibitors: A Population-Based Cohort Study. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 382-384.	2.6	10
160	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. <i>Thrombosis Research</i> , 2019, 182, 12-19.	1.7	10
161	Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. <i>BMJ Open</i> , 2019, 9, e028125.	1.9	10
162	Rates of Infective Endocarditis in Substance Use Disorder and Associated Costs in Ontario. <i>Canadian Journal of Addiction</i> , 2019, 10, 36-43.	0.4	10

#	ARTICLE	IF	CITATIONS
163	Evaluating the early impacts of delisting high-strength opioids on patterns of prescribing in Ontario. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2018, 38, 256-262.	1.1	10
164	Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study. <i>CMAJ Open</i> , 2021, 9, E1128-E1133.	2.4	10
165	Trends in the coprescription of proton pump inhibitors with clopidogrel: an ecological analysis. <i>CMAJ Open</i> , 2015, 3, E428-E431.	2.4	9
166	Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 1120-1122.	2.0	9
167	Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. <i>Drug Safety</i> , 2017, 40, 835-840.	3.2	9
168	Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108238.	3.2	9
169	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. <i>Journal of General Internal Medicine</i> , 2021, 36, 2601-2607.	2.6	9
170	Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003590.	8.4	9
171	Dental Opioid Prescription Characteristics and the Risk of New, Persistent Use. <i>American Journal of Preventive Medicine</i> , 2021, 60, 831-839.	3.0	9
172	Trends and outcomes of serious complications associated with non-fatal opioid overdoses in Ontario, Canada. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108830.	3.2	9
173	Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity score matched cohort study. <i>Addiction</i> , 2022, 117, 1972-1981.	3.3	9
174	The impact of federal warnings on publically funded desmopressin utilization among children in Ontario. <i>Journal of Pediatric Urology</i> , 2012, 8, 249-253.	1.1	8
175	Access to Triptans for Acute Episodic Migraine: A Qualitative Study. <i>Headache</i> , 2015, 55, 199-211.	3.9	8
176	Evaluation of the fentanyl patch-for-patch program in Ontario, Canada. <i>International Journal of Drug Policy</i> , 2019, 66, 82-86.	3.3	8
177	Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 279-284.	5.8	8
178	First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. <i>Canadian Family Physician</i> , 2017, 63, e277-e283.	0.4	8
179	Addressing the overdose crisis in North America with bold action. <i>Addiction</i> , 2022, 117, 1194-1196.	3.3	8
180	Risk of overdose and death following codeine prescription among immigrants. <i>Journal of Epidemiology and Community Health</i> , 2014, 68, 1057-1063.	3.7	7

#	ARTICLE	IF	CITATIONS
181	Rates of Anomalous Bupropion Prescriptions in Ontario, Canada. <i>Annals of Family Medicine</i> , 2015, 13, 343-346.	1.9	7
182	Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study. <i>CMAJ Open</i> , 2016, 4, E292-E297.	2.4	7
183	Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial. <i>BMJ Open</i> , 2017, 7, e015686.	1.9	7
184	The appropriateness and persistence of testosterone replacement therapy in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 119-126.	1.9	7
185	Second-generation anti-depressants and risk of new-onset seizures in the elderly. <i>Clinical Toxicology</i> , 2018, 56, 1179-1184.	1.9	7
186	Measuring the impacts of the <i>Using Antibiotics Wisely</i> campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2472-2478.	3.0	7
187	The association between prescription opioid dispensing and opioid-related morbidity and mortality in Ontario, Canada: an ecological study of public health units. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108989.	3.2	7
188	Identification of Prenatal Opioid Exposure Within Health Administrative Databases. <i>Pediatrics</i> , 2021, 147, .	2.1	7
189	Impact of acetaminophen product labelling changes in Canada on hospital admissions for accidental acetaminophen overdose: a population-based study. <i>Cmaj</i> , 2022, 194, E542-E548.	2.0	7
190	Senior high-cost healthcare usersâ€™ resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada. <i>BMJ Open</i> , 2017, 7, e018488.	1.9	6
191	Trends and uptake of new formulations of controlled-release oxycodone in Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 520-525.	1.9	6
192	Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Olderâ€”A Population-Based Cohort Study. <i>JAMA Internal Medicine</i> , 2019, 179, 1436.	5.1	6
193	Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study. <i>BMJ Open</i> , 2019, 9, e028637.	1.9	6
194	Unplanned index hospital admissions among new older high-cost health care users in Ontario: a population-based matched cohort study. <i>CMAJ Open</i> , 2019, 7, E537-E545.	2.4	6
195	Assessing the impact of an opioid prescribing guideline for dentists in Ontario, Canada. <i>Journal of the American Dental Association</i> , 2020, 151, 43-50.	1.5	6
196	A practical overview and decision tool for analyzing recurrent events in mental illness: A review. <i>Journal of Psychiatric Research</i> , 2021, 137, 7-13.	3.1	6
197	Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: a population-based time series analysis. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109459.	3.2	6
198	Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. <i>International Journal of Drug Policy</i> , 2022, 104, 103680.	3.3	6

#	ARTICLE	IF	CITATIONS
199	Progression through diabetes therapies among new elderly users of metformin: a population-based study. <i>Diabetic Medicine</i> , 2013, 30, e51-e55.	2.3	5
200	Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention. <i>Pharmacotherapy</i> , 2014, 34, 9-18.	2.6	5
201	The impact of policies to reduce blood glucose test strip utilization and costs in Canada. <i>Canadian Journal of Public Health</i> , 2015, 106, e210-e216.	2.3	5
202	Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study. <i>Canadian Urological Association Journal</i> , 2017, 12, E142-5.	0.6	5
203	Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: A population-based study. <i>Respiratory Medicine</i> , 2018, 143, 1-7.	2.9	5
204	Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario. <i>Addiction</i> , 2019, 114, 268-277.	3.3	5
205	Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 12-19.	0.5	5
206	Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada. <i>Canadian Liver Journal</i> , 2021, 4, 51-58.	0.9	5
207	Cohort profile: development and characteristics of a retrospective cohort of individuals dispensed prescription opioids for non-cancer pain in British Columbia, Canada. <i>BMJ Open</i> , 2021, 11, e043586.	1.9	5
208	Prescription opioid characteristics at initiation for non-cancer pain and risk of treated opioid use disorder: A population-based study. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108601.	3.2	5
209	Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. <i>European Urology Focus</i> , 2022, 8, 1433-1440.	3.1	5
210	Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. <i>CMAJ Open</i> , 2021, 9, E1055-E1062.	2.4	5
211	Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. <i>Cmaj</i> , 2022, 194, E556-E560.	2.0	5
212	International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: A cross-sectional analysis of 66 countries. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 779-787.	1.9	5
213	Categorization of Opioid Use Among Pregnant People and Association With Overdose or Death. <i>JAMA Network Open</i> , 2022, 5, e2214688.	5.9	5
214	Extended-release nifedipine and the risk of intestinal obstruction: a population-based study. <i>BMJ Open</i> , 2014, 4, e005377-e005377.	1.9	4
215	Triptans for Acute Migraine: Drug Class Review to Help Inform Policy Decisions. <i>Headache</i> , 2015, 55, 191-198.	3.9	4
216	Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study. <i>Headache</i> , 2015, 55, 212-220.	3.9	4

#	ARTICLE	IF	CITATIONS
217	Retrospective analysis of trends in dispensing long-acting non-tamper-resistant oxycodone near the Canada-United States border. <i>CMAJ Open</i> , 2015, 3, E231-E235.	2.4	4
218	The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-7.	1.6	4
219	Lipophilic β -Blockers and Suicide in the Elderly. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 381-384.	1.4	4
220	Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program. <i>CMAJ Open</i> , 2018, 6, E132-E138.	2.4	4
221	A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 160.	1.9	4
222	Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada. <i>Canadian Liver Journal</i> , 2021, 4, 426-429.	0.9	4
223	Choppy waters: The importance of accounting for shifting drug utilization during the COVID-19 pandemic in future observational drug-related studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 649-651.	2.5	4
224	Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. <i>American Journal of Gastroenterology</i> , 2021, 116, 1738-1740.	0.4	4
225	Adverse event rates associated with oral anticoagulant treatment early versus later after hospital discharge in older adults: a retrospective population-based cohort study. <i>CMAJ Open</i> , 2021, 9, E364-E375.	2.4	4
226	Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003631.	8.4	4
227	Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US-Canada border. <i>Open Medicine</i> , 2012, 6, e141-5.	1.5	4
228	Sevelamer Prescriptions After Reporting of the Dialysis Clinical Outcomes Revisited (DCOR) Trial Findings: An Analysis of 5,495 Patients Receiving Maintenance Dialysis in Ontario, Canada. <i>American Journal of Kidney Diseases</i> , 2011, 57, 357-359.	1.9	3
229	Long-term Analgesic Use: Sometimes Less Is Not More—Reply. <i>Archives of Internal Medicine</i> , 2012, 172, 1189.	3.8	3
230	Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada. <i>Canadian Journal of Diabetes</i> , 2017, 41, 138-142.	0.8	3
231	Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. <i>Neurourology and Urodynamics</i> , 2018, 37, 1693-1700.	1.5	3
232	Fall-Related Hospitalizations in Nursing Home Residents Who Prescribed a Cholinesterase Inhibitor and Beta-Blocker. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2516-2524.	2.6	3
233	Oxycodone, Hydromorphone, and the Risk of Suicide: A Retrospective Population-Based Case-Control Study. <i>Drug Safety</i> , 2020, 43, 737-743.	3.2	3
234	Characteristics of high-cost drug beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis. <i>CMAJ Open</i> , 2020, 8, E297-E303.	2.4	3

#	ARTICLE	IF	CITATIONS
235	Trends in Postpartum Opioid Prescribing: A Time Series Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1004-1010.	4.7	3
236	Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada. <i>Pain</i> , 2022, 163, e129-e136.	4.2	3
237	Evaluating the intended and unintended consequences of opioid-prescribing interventions on primary care in British Columbia, Canada: protocol for a retrospective population-based cohort study. <i>BMJ Open</i> , 2020, 10, e038724.	1.9	3
238	Evaluation of Definitions for Oral Anticoagulant-Associated Major Bleeding: A Population-Based Cohort Study. <i>Blood</i> , 2018, 132, 426-426.	1.4	3
239	New Opioid Use and Risk of Emergency Department Visits Related to Motor Vehicle Collisions in Ontario, Canada. <i>JAMA Network Open</i> , 2021, 4, e2134248.	5.9	3
240	Validation of self-reported opioid agonist treatment among people who inject drugs using prescription dispensation records. <i>Epidemiology</i> , 2021, Publish Ahead of Print, .	2.7	3
241	Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109473.	3.2	3
242	Association of obstructive sleep apnea and opioids use on adverse health outcomes: A population study of health administrative data. <i>PLoS ONE</i> , 2022, 17, e0269112.	2.5	3
243	Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 756-760.	1.9	2
244	Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 256-261.	1.9	2
245	Prenatal Antidepressant Use and Autism Spectrum Disorder—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 665.	7.4	2
246	Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 464-468.	0.9	2
247	The Role of the Medical School Training on Physician Opioid Prescribing Practices: Evidence from Ontario, Canada: Le rôle de la formation à la faculté de médecine à l'égard des pratiques de prescription d'opioïdes des médecins: données probantes d'Ontario, Canada. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 710-720.	1.9	2
248	Opioid use and initiation of positive airway pressure treatment in adults referred for sleep disorder assessment: An explanatory population-based study. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 194-204.	0.5	2
249	Medication use and its impact on high-cost health care users among older adults: protocol for the population-based matched cohort HICOSTT study. <i>CMAJ Open</i> , 2021, 9, E44-E52.	2.4	2
250	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 444-452.	0.9	2
251	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. <i>Healthcare Policy</i> , 2017, 13, 68-78.	0.6	2
252	Comparisons of Insulin Spending and Price Between Canada and the United States. <i>Mayo Clinic Proceedings</i> , 2022, 97, 573-578.	3.0	2

#	ARTICLE	IF	CITATIONS
253	Perioperative opioid-prescribing practices of resident trainees compared with staff surgeons. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 859-860.e2.	1.3	2
254	Interprovincial variation in antibiotic use in Canada, 2019: a retrospective cross-sectional study. <i>CMAJ Open</i> , 2022, 10, E262-E268.	2.4	2
255	Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study. <i>Thrombosis Research</i> , 2022, 213, 57-64.	1.7	2
256	Opioids and Dose-Related Deaths—Association or Causation?—Reply. <i>Archives of Internal Medicine</i> , 2011, 171, 1687.	3.8	1
257	Antidepressant use, serotonin transporter affinity, and reinfarction among patients receiving clopidogrel: a population-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1328-1333.	1.9	1
258	Reply to Strandberg and Tienari. <i>Clinical Infectious Diseases</i> , 2014, 58, 1043-1044.	5.8	1
259	Off-label use of inhaled tobramycin in Ontario, Canada. <i>Thorax</i> , 2016, 71, 862-864.	5.6	1
260	Impact of a Graduated Approach on Opioid Initiation and Loss of Earnings Following Workplace Injury. <i>Journal of Occupational and Environmental Medicine</i> , 2017, 59, 1197-1201.	1.7	1
261	Trends in opioid use before critical illness among elderly patients in Ontario. <i>Journal of Critical Care</i> , 2020, 55, 128-133.	2.2	1
262	Impact of Clinical Practice Guidelines on Blood Glucose Test Strip Prescription Rates in Manitoba and Saskatchewan (Canada): An Interrupted Time-Series Analysis. <i>Canadian Journal of Diabetes</i> , 2021, 45, 557-565.e2.	0.8	1
263	Greater than the Sum: Applying Daily-Dose Equivalents to Antipsychotic Prescription Claims to Study Real-World Effects. <i>Frontiers in Pharmacology</i> , 2021, 12, 709349.	3.5	1
264	Concordance between high antibiotic prescribing and high opioid prescribing among primary care physicians: a cross-sectional study. <i>CMAJ Open</i> , 2021, 9, E175-E180.	2.4	1
265	Varenicline and Risk of Self-Harm: A Nested Case-Control Study. <i>PLoS ONE</i> , 2016, 11, e0163681.	2.5	1
266	Language proficiency and warfarin-related adverse events in older immigrants and Canadian residents: a population-based cohort study. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 590-598.	0.6	1
267	The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis. <i>CMAJ Open</i> , 2021, 9, E1181-E1186.	2.4	1
268	Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion. <i>JAMA Network Open</i> , 2022, 5, e2143050.	5.9	1
269	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 444-452.	0.9	1
270	Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors. <i>Canadian Journal of Hospital Pharmacy</i> , 2022, 75, 104-107.	0.1	1

#	ARTICLE	IF	CITATIONS
271	Opioid prescribing practices in chronic kidney disease: a population-based cohort study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2408-2417.	0.7	1
272	Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study. <i>Canada Communicable Disease Report</i> , 2022, 48, 170-178.	1.3	1
273	The Risk of Ventricular Dysrhythmia or Sudden Death in Patients Receiving Serotonin Reuptake Inhibitors With Methadone: A Population-Based Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 861953.	3.5	1
274	Identifying the changing age distribution of opioid-related mortality with high-frequency data. <i>PLoS ONE</i> , 2022, 17, e0265509.	2.5	1
275	Evaluating the population-level effects of oxycodone restrictions on prescription opioid utilization in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	1
276	Cost Minimal Effectiveness of SMBG. <i>Canadian Journal of Diabetes</i> , 2010, 34, 180.	0.8	0
277	Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 803-807.	1.4	0
278	More Rigorous Study Needed Before Claiming No Harm of Blood Glucose Test Strip Limits for Patients Using Insulin—Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 890.	5.1	0
279	Do Diagnostic and Procedure Codes Within Population-Based, Administrative Datasets Accurately Identify Patients with Rectal Cancer?. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 367-376.	1.7	0
280	Comparison of claims from high-cost drug beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis. <i>CMAJ Open</i> , 2021, 9, E1048-E1054.	2.4	0
281	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	0